Skip to main content

Table 2 (abstract O17). Monthly migraine headache days with acute medication use, average of months 1-6

From: 12th European Headache Federation Congress jointly with 32nd National Congress of the Italian Society for the Study of Headaches

 

LFEM

HFEM

 

Treatment

Baseline meana (SD)

N

LSM change from baseline ± SE

LSM change difference ± SE

p-valueb

Baseline meana (SD)

N

LSM change from baseline ± SE

LSM change difference ± SE

p-valueb

p-valuec

Placebo

4.8 (1.7)

295

-0.8 ± 0.2

  

8.9 (3.3)

580

-2.7 ± 0.2

   

Galca 120mg

4.8 (1.8)

150

-2.4 ± 0.2

-1.7 ± 0.2

<.001

8.8 (3.4)

286

-4.6 ± 0.2

-1.9 ± 0.2

<.001

.493

Galca 240mg

4.9 (1.7)

145

-2.1 ± 0.2

-1.4 ± 0.2

<.001

8.7 (3.1)

283

-4.6 ± 0.2

-1.9 ± 0.2

<.001

.152

  1. Galca galcanezumab, N number of subjects who have a non-missing baseline value and at least one post-baseline value;
  2. aBased upon subjects with a non-missing baseline value; b p-value vs. placebo; cTreatment-by-subgroup interaction p-value vs. placebo
Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us